Is AVEO a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,381 people get AVEO articles and Market Currents by email alert.

Get email alerts on AVEO »

HEADLINES:

Complete Seth Klarman And Baupost Group Portfolio Update
Profit Fan • Wed, May 15 • 3 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q1 2013 Update
John Vincent • Wed, May 15 • 3 Comments
Billionaire Seth Klarman's Long-Term Stock Picks
Insider Monkey • Mon, May 13
Seth Klarman's Worst Performing Stock Picks Year-To-Date
Profit Fan • Mon, May 13 • 11 Comments
Top Small-Cap Biotech Stocks Being Accumulated By Large Fund Managers
GuruFundPicks • Tue, May 7 • 8 Comments
Looking For Opportunity - 5 Biotechs That Crashed
Craig Keolanui • Mon, May 6 • 13 Comments
AVEO: Here's Looking At You, FDA
Bond Wells • Sat, May 4 • 17 Comments
The ODAC Postmortem: Lessons Learned Part 1, AVEO
PropThink • Fri, May 3 • 16 Comments
AVEO Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 3 • 3 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Fri, May 3 • 2 Comments
Aveo Gets Bad News On Tivozanib
Derek Lowe • Thu, May 2 • 18 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Wed, May 1 • 3 Comments
Cramer's Mad Money - 16 Things To Watch In The Week Ahead (4/26/13)
SA Editor Miriam Metzinger • Sun, Apr 28 • 5 Comments
Aveo's Inflection Point: Tivozanib Likely To Receive Positive Advisory Vote, FDA Approval
PropThink • Wed, Apr 24 • 37 Comments
Quickly Approaching Biopharma Catalyst Events
Scott Matusow • Wed, Apr 24 • 22 Comments
Aveo's Upcoming AdCom - Tivozanib's Safety Will Lead The Way Towards Approval
Bioassociate Consulting • Mon, Apr 22 • 4 Comments
Thursday's BioPharma Trade Movers
Scott Matusow • Thu, Apr 18 • 30 Comments
AVEO Poised To Move Higher Before FDA Adcomm Catalyst, Obamacare And Platform Potential
Scott Matusow • Tue, Apr 16 • 43 Comments
Why We Expect The FDA To Approve Aveo's Tivozanib
Chris Rees • Tue, Apr 16 • 7 Comments
2 Oncology Biotechs For The Future
Bio Matt • Sun, Apr 14 • 10 Comments

To learn more about Seeking Alpha Pro, click here.

AVEO: Here's Looking At You, FDA
Bond Wells • Sat, May 4 • 17 Comments
The ODAC Postmortem: Lessons Learned Part 1, AVEO
PropThink • Fri, May 3 • 16 Comments
Aveo Gets Bad News On Tivozanib
Derek Lowe • Thu, May 2 • 18 Comments
Aveo's Inflection Point: Tivozanib Likely To Receive Positive Advisory Vote, FDA Approval
PropThink • Wed, Apr 24 • 37 Comments
Aveo's Upcoming AdCom - Tivozanib's Safety Will Lead The Way Towards Approval
Bioassociate Consulting • Mon, Apr 22 • 4 Comments
AVEO Poised To Move Higher Before FDA Adcomm Catalyst, Obamacare And Platform Potential
Scott Matusow • Tue, Apr 16 • 43 Comments
Why We Expect The FDA To Approve Aveo's Tivozanib
Chris Rees • Tue, Apr 16 • 7 Comments
Why AVEO Pharmaceuticals' Tivozanib Will Be Approved For The Treatment Of Advanced Renal Cell Carcinoma
Robert Schwartz • Wed, Mar 20 • 33 Comments
Is AVEO's Tivozanib Any Better Than Placebo For The Treatment Of Renal Cell Carcinoma?
Richard Daifuku • Thu, Mar 14 • 18 Comments
AVEO: Final Overall Survival Results From The TIVO1 Study
Ben Yoffe • Wed, Feb 13 • 3 Comments
Tivozanib And AVEO: Valuation Suggests Upside Ahead Of FDA Decision
PropThink • Fri, Dec 28, 2012 • 5 Comments
Upcoming FDA Decision For AVEO's Tivozanib Builds Speculation
Brian L. Wilson • Fri, Dec 21, 2012 • 3 Comments
Aveo Pharmaceuticals: A Hidden Gem Or A Hidden Disaster
John Li • Mon, Dec 10, 2012 • 7 Comments
Upcoming Catalyst Event For Aveo Pharma May Provoke Short Covering
Scott Matusow • Wed, Nov 21, 2012 • 17 Comments
AVEO Pharmaceuticals: Attractive Following Recent De-Risking Events
Ohad Hammer • Mon, Oct 22, 2012 • 7 Comments
AVEO Management Excited About Statistically Significant Improvement Shown In Phase III TIVO-1 Trial
M. E. Garza • Wed, Oct 3, 2012 • 4 Comments
Does AVEO Pharmaceuticals' Tivozanib Work, Or Not?
Derek Lowe • Wed, Aug 8, 2012 • 12 Comments
AVEO: More Open Questions Than Answers
Ohad Hammer • Sun, Jan 8, 2012 • 12 Comments
Biotech IPO: AVEO Pharma Develops Cancer Therapeutics
SA Editor Mohit Manghnani • Thu, Mar 11, 2010

Complete Seth Klarman And Baupost Group Portfolio Update
Profit Fan • Wed, May 15 • 3 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q1 2013 Update
John Vincent • Wed, May 15 • 3 Comments
Billionaire Seth Klarman's Long-Term Stock Picks
Insider Monkey • Mon, May 13
Seth Klarman's Worst Performing Stock Picks Year-To-Date
Profit Fan • Mon, May 13 • 11 Comments
Top Small-Cap Biotech Stocks Being Accumulated By Large Fund Managers
GuruFundPicks • Tue, May 7 • 8 Comments
Looking For Opportunity - 5 Biotechs That Crashed
Craig Keolanui • Mon, May 6 • 13 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Fri, May 3 • 2 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Wed, May 1 • 3 Comments
Cramer's Mad Money - 16 Things To Watch In The Week Ahead (4/26/13)
SA Editor Miriam Metzinger • Sun, Apr 28 • 5 Comments
Quickly Approaching Biopharma Catalyst Events
Scott Matusow • Wed, Apr 24 • 22 Comments
Thursday's BioPharma Trade Movers
Scott Matusow • Thu, Apr 18 • 30 Comments
2 Oncology Biotechs For The Future
Bio Matt • Sun, Apr 14 • 10 Comments
3 Healthcare Stocks Waiting For The FDA's Approval
Emerging Equities • Fri, Apr 5
3 Small Cap Biopharmas Primed To Move Much Higher Now
Scott Matusow • Wed, Mar 27 • 12 Comments
2 Cancer Biotechs With Upcoming FDA Approval Decisions In 2013
David Zanoni • Fri, Mar 22 • 19 Comments
Bio Run-Ups: What To Expect In The Next Few Months
Alexander Maxwell • Fri, Mar 22 • 33 Comments
Astellas Needs To Pick A Model To Prosper
Stephen Simpson • Thu, Feb 21
A Review Of Seth Klarman's Baupost Group's Q4 U.S. Equity Changes
Zvi Bar • Mon, Feb 18 • 3 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q4 2012 Update
John Vincent • Thu, Feb 14 • 2 Comments
5 Biotech Companies With Recent CEO Purchases
Kevin Quon • Fri, Jan 4 • 1 Comment

AVEO Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 3 • 3 Comments
AVEO Pharmaceuticals' Management Presents at Barclays Global Healthcare Conference (Transcript)
Wed, Mar 13
AVEO Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 13
AVEO Pharmaceuticals Management Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Oct 30, 2012
AVEO Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012

Cramer's Homework Uncovers Stock Concerns

at CNBC.com (Apr 26, 2013)
AVEO Announces Exercise of Over-Allotment Option for Recent Public Offering

Business Wire (Jan 22, 2013)
AVEO Prices Public Offering of Common Stock

Business Wire (Jan 17, 2013)
Midday Movers: TEA, SBUX, ARO & More

at CNBC.com (Nov 14, 2012)
Earnings Watch: Updates, advisories and surprises

at MarketWatch.com (Aug 2, 2012)
Movers & Shakers: Thursday’s biggest gaining and declining stocks

at MarketWatch.com (Aug 2, 2012)
AVEO Reports First Quarter 2012 Financial Results and Recent Developments

Business Wire (May 3, 2012)
AVEO Announces Preliminary Results of Exploratory Phase 2 Study Evaluating HGF Inhibitor in First-Line Patients with Advanced Lung Cancer

Business Wire (May 2, 2012)
AVEO Pharmaceuticals, Inc. to Present at Upcoming Investment Conferences

Business Wire (Apr 30, 2012)
AVEO Pharmaceuticals, Inc. Announces Timing for First Quarter Financial Results, Webcast and Conference Call

Business Wire (Apr 26, 2012)
AVEO Announces Publication of Positive Tivozanib Phase 2 Clinical Trial Results in Journal of Clinical Oncology

Business Wire (Apr 12, 2012)
Data on AVEO Pharmaceuticals’ Tivozanib and AV-203 to Be Presented at AACR Annual Meeting 2012

Business Wire (Mar 27, 2012)
AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial

Business Wire (Jan 3, 2012)
AVEO Pharmaceuticals, Inc. Announces Webcast and Conference Call

Business Wire (Jan 2, 2012)
AVEO Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference

Business Wire (Dec 28, 2011)
AVEO Announces Patient Enrollment in Phase 2 Clinical Trial of Tivozanib in Combination with mFOLFOX6 in Patients with Advanced Colorectal Cancer

Business Wire (Dec 22, 2011)
Earnings Watch: Updates, advisories and surprises

at MarketWatch.com (Jul 28, 2011)
Movers & Shakers: Wednesday’s biggest gaining and declining stocks

at MarketWatch.com (Jun 15, 2011)
Biotech Stocks: Regeneron energizes biotech stocks

at MarketWatch.com (Jun 15, 2011)
Biotech Stocks: Inspire, AVEO take lead in drug-stocks trading

at MarketWatch.com (Feb 17, 2011)

AVEO vs. ETF Alternatives

Company Description

Currently, there's no company description for AVEO.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 24, 9:10 AM Premarket gainers: BLOX +17%. IOC +15%. YGE +13%. P +11%. MRVL +5%.
Losers: DF -52%. SHLD -16%. AVEO -15%. RSOL -13%. TITN -11%. APPY -7%. ANF -7%. CRM -5%. 2 Comments [On the Move]
Thursday, May 23, 6:21 PM AVEO Pharmaceuticals (AVEO) has been informed by its partner, Astellas Pharma (ALPMY.PK), that it no longer intends to submit a Marketing Authorization Application to the European Medicines Agency for tivozanib, its treatment for advanced renal cell carcinoma, nor does not intend to fund any future trials under its strategic collaboration agreement. AVEO says it's evaluating the impact of the news and its options for the drug going forward. AVEO -14.7% AH. Comment! [Healthcare, Global & FX, On the Move]
Thursday, May 23, 5:33 PM After-hours top gainers, as of 5:15 p.m.: BLOX +18.2%. P +8.7%. MRVL +7.7%. NSPR +2.7%. OHI +2.4%.
After-hours top losers: AVEO -13.3%. WETF -11.9%. SHLD -11.5%. TITN -11.1%. I -8.1%. Comment! [On the Move]
Wednesday, May 15, 9:14 AM Premarket gainers: CHCI +41%. DVR +25%. CLNT +14%. VIPS +13%. EJ +11%. AFFY +9%. CHLN +9%. SPWR +8%. AVEO +5%.
Losers: XONE -10%. RMTI -8%. WMC -5%. 2 Comments [On the Move]
Friday, May 3, 9:54 AM Delcath Systems (DCTH -48.9%) collapses after the FDA votes unanimously against the company's Melblez Kit, as the risks purportedly outweigh the benefits. The shares were halted Thursday pending the announcement. DCTH is the second casualty of this week's Oncologic Drugs Advisory Board, as Aveo Pharmaceuticals (AVEO +1.5%) received a similarly disappointing panel vote on Tivozanib. (Background: I, II) Comment! [Healthcare, On the Move]
Thursday, May 2, 1:27 PM Shares of Aveo Pharmaceutical (AVEO -48%) resume trading after being halted earlier in the day following an FDA panel vote of 13 to 1 that its application for Tivozanib did not demonstrate a favorable benefit-to-risk evaluation for the treatment of advanced renal cell carcinoma. Comment! [Healthcare, On the Move]
Tuesday, April 30, 12:46 PM Midday top 10 gainers: TTHI +45%. PTIE +26%. DRRX +26%. MTOR +23%. MGAM +20%. OIS +16%. GIB +14%. HGSH +15%. ARWR +13%. TXRH +13%.
Midday top 10 losers: DCTH -44%. AVEO -26%. NUAN -18%. AOSL -18%. PBI -16%. AEIS -13%. MSTR -10%. ANV -10%. ELTK -10%. SYN -10%. Comment! [On the Move]
Tuesday, April 30, 9:10 AM Premarket gainers: HPY +10%. HTWR +9%. ANAD +9%. AVP +8%. UBS +7%. BBY +6%.
Losers: DCTH -20%. AVEO -16%. NUAN -15%. PBI -10%. MTG -8%. CNH -6%. RVBD -6%. QGEN -5%. Comment! [On the Move]
Tuesday, April 30, 9:01 AM Shares of Aveo Pharmaceuticals (AVEO) fall 17% premarket as the FDA asks the Oncologic Drugs Advisory Committee to help evaluate whether a single randomized trial is sufficient to warrant marketing approval for AVEO's renal cell carcinoma treatment tivozanib or whether further testing is necessary. Comment! [Healthcare, On the Move]
Monday, April 29, 6:39 AM Aveo Pharmaceuticals (AVEO): Q1 EPS of -$0.69 beats by $0.03. Revenue of $300K. (PR) Comment! [Breaking News, Earnings, Healthcare]
Thursday, April 25, 9:12 AM Premarket gainers: MPG +23%. INFN +19%. AKAM +17%. FIO +16%. CLF +8%. YNDX +7%. NXST +7%. NOW +7%. CAB +6%. CAKE +6%.
Losers: XIDE -15%. WHX -14%. INTU -13%. ZNGA -9%. MLNX -8%. AVEO -7%. CTXS -7%. 1 Comment [On the Move]
Wednesday, April 3, 5:35 PM After-hours top gainers, as of 5:15 p.m.: CCG +8%. ANV +5%. AVEO +4%. GFI +3%. VALE +2%.
After-hours top losers: SFUN -6%. IMUC -3%. CPWR -3%. LSE -3%. ROC -2%. Comment! [On the Move]
Wednesday, February 13, 9:29 AM AVEO Pharma (AVEO) -12.5% premarket even as its Q4 net loss narrowed from the year-ago quarter, primarily due to a milestone from Astellas recognized upon the acceptance of a new drug filing. But AVEO also announced disappointing results for its tivozanib drug from a Phase 3 TIVO-1 study in patients with advanced renal cell carcinoma. Comment! [Healthcare, Earnings, On the Move]
Wednesday, February 13, 9:10 AM Premarket gainers: RCON +56%. PPHM +17%. EZCH +11%. WFR +9%. CMCSA +8%. GRPN +8%. VG +5%.
Losers: RATE -18%. CLF -14%. RAX -12%. AVEO -11%. AMX -6%. DF -6%. NICE -5%. Comment! [On the Move]
Wednesday, February 13, 6:37 AM AVEO Pharma (AVEO): Q4 EPS of -$0.49 beats by $0.16. Revenue of $15.5M beats by $1.01M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, February 13, 12:05 AM Notable earnings before Wednesday’s open: ASPS, AVEO, CPN, DE, DF, DPS, DUK, EZCH, FBN, H, HSP, LO, PES, PRLB, TLM, TRI, VG, WCG, WFR 1 Comment [Earnings]

Chemist357
just opened a long position in $AVEO appears bottom has stabalized
Wed, 1:58 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Alp Bugra Basat
$Bottom fishers buy $AVEO, mentioned several days ago in my stock twitter @ http://bit.ly/10MGJjt
Sat, 6:43 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jason F
Trades ideas for the Bull & Bears for $AVEO http://bit.ly/13oLROJ
May 11, 2:35 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Brian L. Wilson
Here is why the $AVEO vote was so horrendous http://bit.ly/YpJ2gG
May 2, 4:11 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Webb
$AVEO 13-1 as I predicted: http://seekingalpha.com/a/t9px Pump! Pump! Pump! Boom!
May 2, 1:43 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
Check out what a Member of the upcoming $AVEO Adcomm has to say about RCC drugs with PFS improvement. http://bit.ly/14UYRi8
May 1, 10:52 AM
Reply (6)

• !Report Abuse
View all 6 replies
Scott Matusow: yes
May 3, 8:40 AM
• !Report Abuse
stuckk: what about Aveo now ?
May 3, 1:34 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$AVEO getting closer to my price target, go!
Apr 23, 11:34 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Speedy12
$AVEO Institutions own ~75% of AVEO. 5 made their 13F filings for Mar 31 already and they bought net ~1 million shares or 22.3% increase.
Apr 20, 4:13 PM
Reply (1)

• !Report Abuse
View all 1 replies
Speedy12: My guess is other institutions added as well. Also recent strong insider buying. Wise to follow the "SMART" money.
Apr 20, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Red Acre Investments
Binary Event Watch April 2013 - Part II http://bit.ly/114CVMl ... $RPTP $AVEO $DCTH $VVUS $SRPT $PFE $DRRX $PTIE $TTNP $XNPT $EXAS
Apr 12, 12:25 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Red Acre Investments
April binary event watch pt2 $PFE $RPTP $TTNP $AVEO $DCTH $PFE $SRPT $VVUS $AGN $DRRX $PTIE $XNPT $EXAS get it free: http://bit.ly/10SbDco
Apr 11, 7:03 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Scott Matusow
Check out what a Member of the upcoming $AVEO Adcomm has to say about RCC drugs with PFS improvement. http://bit.ly/14UYRi8
May 1, 10:52 AM
Reply (6)

• !Report Abuse
View all 6 replies
Scott Matusow: yes
May 3, 8:40 AM
• !Report Abuse
stuckk: what about Aveo now ?
May 3, 1:34 PM
• !Report Abuse
Add a reply...

140 characters

Speedy12
$AVEO Institutions own ~75% of AVEO. 5 made their 13F filings for Mar 31 already and they bought net ~1 million shares or 22.3% increase.
Apr 20, 4:13 PM
Reply (1)

• !Report Abuse
View all 1 replies
Speedy12: My guess is other institutions added as well. Also recent strong insider buying. Wise to follow the "SMART" money.
Apr 20, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Anyone want to bet me that $AVEO is over $7 by next week? any takers?
11/21/12
Reply (17)

• !Report Abuse
View all 17 replies
JMEaramn: what made AVEO drop so much after getting approved
12/2/12
• !Report Abuse
smokeyRose: EveryBody took their profits maybe?
12/5/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Anyone want to bet me that $AVEO is over $7 by next week? any takers? Wed, 11:42 AM << they shorted, they lose
11/23/12
Reply (6)

• !Report Abuse
View all 6 replies
Scott Matusow: nah . lol $AVEO was a very easy call
11/23/12
• !Report Abuse
1980XLS-2.0: Shorted for .60 cent (10%) gain & fast. THX
11/30/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$LGND $19.05 alerted at $16.60 $BGMD $1.35 alerted at $1.05 $AVEO $6.80 alerted at $6.60 $FOLD $4.85 alerted at $4.35
11/23/12
Reply (4)

• !Report Abuse
View all 4 replies
blakhalo: CPRX $.52 alerted at $1.88 -/+
11/26/12
• !Report Abuse
Scott Matusow: blak, u must lose money in the market -- I also gave a price target of $2.25 after financing -- that's on traders, now learn to make money
11/26/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I think $ANAC hits $6 by late this week/ early next week, any takers? U lost on $AVEO
11/26/12
Reply (4)

• !Report Abuse
View all 4 replies
ckang: Scott, are you writing articles on $ANAC?
11/26/12
• !Report Abuse
GVT: Scott - $CLSN, any idea on how Phase3 data is going to shape up ?
11/26/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Huge call volume on $AVEO over 1600 contracts dec calls $7.50 strike
11/21/12
Reply (1)

• !Report Abuse
View all 1 replies
Noreika: Received your heads up yesterday. Another nice call I didn't play. I'm still all in VRNG waiting for something/anything. Have a good holiday
11/21/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I bought more $AVEO I like this one after reading data, NDA should be accepted, 70 - 80% shot, way undervalued, plenty of cash on hand
11/20/12
Reply (2)

• !Report Abuse
View all 2 replies
Nahodny Okoloiduci: i don't like yesterdays AH action (at not much volume, though).. arent't you afraid of massive inst selling if it dips below $5?
11/21/12
• !Report Abuse
Scott Matusow: it was a misprint i watch af trading, it was a carry over trade from reg session 6.59. mis printed as 5.59
11/21/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
CORRECTION: Alert, I bought @$6.60 $AVEO as run-up ahead of FDA Decision on Tivozanib 11/28/12
11/20/12
Reply (4)

• !Report Abuse
View all 4 replies
Scott Matusow: PT is $9 on NDA acceptance.
11/20/12
• !Report Abuse
rseiter: Probably a buyout too? Avon perhaps......
11/20/12
• !Report Abuse
Add a reply...

140 characters

AVEO AVEO Pharmaceuticals, Inc.

AVEO

AVEO Pharmaceuticals, Inc.